We represented Envision Healthcare Corporation (NYSE: EVHC) in its sale to KKR in an all-cash transaction for $9.9 billion, including debt. KKR paid $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company’s volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction closed in October 2018.
Bass, Berry & Sims has served as primary corporate and securities counsel to Envision for more than 20 years.
The transaction was also covered by various media outlets, including:
- “KKR to Acquire Envision Healthcare for $5.5 Billion,” The Wall Street Journal (June 11, 2018)
- “Simpson Thacher Leads KKR In $9.9B Envision Healthcare Buy,” Law360 (June 11, 2018)
- “K.K.R. Said to Be Near Deal to Acquire Envision Healthcare,” The New York Times (June 10, 2018)
Envision Healthcare Corporation is a leading provider of physician-led services and post-acute care, and ambulatory surgery services. As of December 13, 2018, they delivered physician services, primarily in the areas of emergency department and hospitalist services, anesthesiology services, radiology/tele-radiology services and children’s services to more than 1,800 clinical departments in healthcare facilities in 45 states and the District of Columbia.
KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, growth equity, energy, infrastructure, real estate and credit, with strategic manager partnerships that manage hedge funds.